WebConclusion: Pemetrexed plus platinum doublet regimen is an efficacious treatment for advanced nonsquamous NSCLC patients. Our findings support the use of pemetrexed plus platinum doublet regimen as first-line treatment in advanced nonsquamous NSCLC patients because of its potential survival benefits. WebApr 17, 2024 · The PACIFIC study [NCT02125461] was a phase 3, randomized, placebo-controlled study of patients with stage III [locally advanced, unresectable non–small cell lung cancer] who did not progress after definitive chemo-radiotherapy and were 18 or older, performance status 1, life expectancy 12 weeks or more, all-comers population, 1 to 42 …
Non-Small Cell Lung Cancer Treatment Regimens
WebJul 13, 2024 · - Pemetrexed plus carboplatin for NSCLC and mesothelioma - Pemetrexed plus cisplatin NSCLC and meso regimen - Gemcitabine plus carboplatin for non-small … WebApr 11, 2024 · Approximately 20 to 25% of patients who receive a diagnosis of non–small-cell lung cancer (NSCLC) have resectable disease 1; however, 30 to 55% of patients … opal handy
NON-SMALL CELL LUNG CANCER TREATMENT …
Web2.1 Recommended Dosage for Non-Squamous NSCLC. The recommended dose of Pemetrexed for Injection when administered with cisplatin for initial treatment of locally … WebMar 24, 2024 · The addition of Keytruda to Alimta - platinum chemotherapy further improved survival in NSCLC. The KEYNOTE-189 clinical trial evaluated Keytruda in combination with Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy for the first-line treatment of patients with NSCLC regardless of programmed death-ligand 1 (PD-L1) expression. WebPemetrexed – either alone or in combination with other chemotherapy regimens – was effective among NSCLC patients with EGFR mutations who experienced resistance or disease progression after failure of EGFR -TKI treatment, with PFS ranging from 2.7 to 6.4 months and a weighted median PFS of 5.09 months ( Table 2 ). iowa drainage districts